Cogent Biosciences, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Cogent Biosciences, Inc. (COGT) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $14.21 million as of 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-17
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $14.21M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $7.77M.
- 2023-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $9.16M.
- 2022-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $10.63M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $14.21M 10-K · filed 2026-02-17 |
| 2024-12-31 | $7.77M 10-K · filed 2025-02-25 |
| 2023-12-31 | $9.16M 10-K · filed 2024-02-26 |
| 2022-12-31 | $10.63M 10-K · filed 2023-03-14 |
| 2022-09-30 | $12.71M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $10.71M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $886.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $183.00K 10-K · filed 2022-03-15 |
| 2021-09-30 | $463.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $347.00K 10-Q · filed 2021-08-16 |
| 2021-03-31 | $446.00K 10-Q · filed 2021-05-12 |
| 2020-12-31 | $555.00K 10-K · filed 2021-03-16 |
| 2020-09-30 | $677.00K 10-Q · filed 2020-11-09 |
| 2019-12-31 | $625.00K 10-K · filed 2020-03-26 |
| 2019-09-30 | $719.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $819.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | $923.00K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |